L-arabinose genuinely inhibits sucrase, the gut enzyme that splits table sugar. Add it to a sugary drink and glucose and insulin peaks measurably drop. Add the same thing to a normal meal with solid food and three independent trials found essentially nothing. It's a real mechanism with a narrow window — and the doses that worked were measured in grams, which is the detail that matters most when you're looking at a capsule.
What L-arabinose is, and what Sukre is
L-arabinose is a pentose — a five-carbon sugar — found in plant cell walls, in beet pulp, corn fibre and various gums. It tastes faintly sweet and your body barely absorbs it as fuel.
Sukre is a brand name, not a different substance. When a label says Sukre, the active compound is L-arabinose. Trademarking an ingredient is standard practice in this industry: it implies proprietary science, it makes comparison shopping harder, and it means a search for the brand won't turn up the unflattering trials. Worth knowing before you conclude that Sukre has its own evidence base. It doesn't — it has L-arabinose's, which is what this page is about.
The mechanism, which is the good part
Table sugar is sucrose: one glucose stuck to one fructose. You can't absorb it in that form. An enzyme in your small intestine called sucrase has to cut it in half first, and only then does the glucose enter your blood.
L-arabinose inhibits sucrase. Block the enzyme, and the sucrose passes through undigested instead of becoming blood glucose. In vitro work has shown this inhibition clearly, on both sucrase and maltase.1
What I like about this mechanism is that it's specific and falsifiable. It doesn't claim to "support healthy glucose metabolism" through some unfalsifiable cascade. It makes a narrow, testable prediction: give someone sucrose with L-arabinose and their glucose curve should be flatter. That prediction has been tested. Let's look at what happened.
Test one: the sugary drink. It works.
This is the scenario L-arabinose was built for, and it delivers.
A 2021 study from Pol and Mars tested L-arabinose added to realistic foods.2 In the drink condition, glucose responses were significantly lower than control (P < 0.01). Straightforward confirmation of the mechanism.
A 2025 randomised, double-blind, cross-over trial went further and tested people who actually need help: 18 adults with impaired fasting glucose, average age 73.3 That's a genuinely relevant population — prediabetic, older, the people these products are marketed to. When L-arabinose was added to a sucrose-rich drink:
- Glucose peaks fell 14%
- Insulin peaks fell 30%
- Both peaks were delayed — glucose by 10 minutes, insulin by 32
- Continuous glucose monitoring showed reduced variability: standard deviation −25%, coefficient of variation −24%, mean amplitude of glycaemic excursions −26%
A 30% cut in the insulin peak is not a trivial finding. If you stopped reading here you'd conclude L-arabinose is one of the better-evidenced ingredients in this category, and for that specific scenario you'd be right.
Test two: an actual meal. It doesn't.
Here's the part that changes the picture, and it has been replicated three times by different groups.
2015: mixed meals, nothing
Halschou-Jensen and colleagues set out to reproduce the sugar-drink result in people eating breakfast.4 Seventeen healthy men, randomised, double-blind, cross-over, with meals containing sucrose and wheat starch supplemented with 0%, 5% or 10% L-arabinose by weight. A second study tested different food textures and a maltose liquid meal at up to 20% L-arabinose.
The result: peak plasma concentration, time to peak, and AUC for glucose, insulin and C-peptide were all unchanged. The authors' conclusion was blunt — it was not possible to reproduce the beneficial effects when L-arabinose was mixed into a solid or semi-solid meal.
2021: the drink worked, the muffin didn't
The same study that confirmed the drink effect also tested a muffin.2 Glucose responses after the muffin were not significantly different; the insulin peak merely "tended to be lower." The authors concluded that efficacy appears to depend on the food matrix — the same ingredient, the same dose, a different physical form, and the effect evaporates.
2025: the drink worked, the diet didn't
The trial in prediabetic adults had two phases. The single sucrose-rich drink gave the strong results above. But the study also ran a controlled sucrose-rich diet of complex meals and snacks, and there no effects on glycaemic variability were observed at all.3 The authors stated plainly that the effect did not extend to a sucrose-rich diet containing complex meals.
Three trials, three research groups, one conclusion. 2015, 2021 and 2025 all found the same thing: isolated sucrose in liquid form, the effect is real; food as people actually eat it, the effect disappears. That level of agreement is rare in supplement research, and it is pointing in an inconvenient direction for anyone selling this.
Why the food matrix matters so much
Nobody has definitively explained it, but the leading candidates are sensible:
- Dilution and contact. Enzyme inhibition requires the inhibitor to physically reach the enzyme at sufficient concentration at the right moment. In a drink, L-arabinose and sucrose arrive together, evenly mixed. In a solid meal, they're distributed through a bolus of fat, protein and fibre.
- Gastric emptying. The 2015 study used paracetamol as a marker for exactly this reason. Solid meals leave the stomach slowly and unevenly, spreading sucrose delivery over a long window and blunting any single-point intervention.
- Competing substrates. Starch from wheat flour is digested by different enzymes into glucose that L-arabinose does nothing about. If a meaningful share of your meal's glucose isn't coming from sucrose, blocking sucrase can't touch it.
That last point deserves emphasis, because it's a limitation of the mechanism rather than of the delivery. L-arabinose only acts on sucrose. Bread, rice, potatoes, pasta, oats — starch, not sucrose. If your glucose problem is a bowl of pasta, this ingredient is mechanically irrelevant to it no matter how it's delivered.
The dose problem
Now the arithmetic, which is where this connects to what's actually for sale.
In every trial above, L-arabinose was dosed as a percentage of the sugar's weight — typically 5% to 15% w/w, and up to 20% in one arm. That's the right way to dose an enzyme inhibitor: the more substrate, the more inhibitor you need.
Run the numbers on a real drink. A regular 500 ml soft drink holds roughly 50 g of sugar. At 10% w/w you need 5 grams of L-arabinose. Even a modest 20 g of sucrose — two teaspoons in coffee and a biscuit — calls for 2 g.
Now look at a capsule. Gluco6 is built on Sukre, and its entire botanical blend is 525 mg covering seven ingredients. Even in the impossible case where all 525 mg were L-arabinose and the other six botanicals were imaginary, that is roughly a tenth of the dose used in the trial that worked. The real figure is unknowable, because the blend is proprietary and individual weights aren't disclosed — but it cannot be anywhere near 5 g, because 5 g is nearly ten times the whole blend.
There's a second mismatch on top of the first. In the trials, L-arabinose was mixed into the sugary drink itself — inhibitor and substrate arriving together, perfectly combined. A once-daily capsule swallowed at some point in the day cannot reproduce that, and the food-matrix findings above suggest the separation matters a great deal.
To be fair to the ingredient: none of this means L-arabinose doesn't work. It means the conditions under which it has been shown to work — grams of it, mixed directly into a sugary liquid — are not the conditions under which it is usually sold. Those are different criticisms, and only the second one is about the product.
Who funded all this
Worth stating plainly, in both directions.
The 2021 study was funded by Royal Cosun, and the 2025 trial received supplies from the Cosun Innovation Center. Cosun is a commercial producer of L-arabinose. Industry funding is a legitimate reason for extra scrutiny.
But notice which way it cuts here. These industry-funded studies are the ones that reported the negative findings — the muffin that didn't work, the controlled diet that showed nothing. A sponsor's own research publishing the limits of its ingredient is a point in favour of taking those limits seriously. The 2015 mixed-meal study, which found nothing at all, came from an independent Danish group.
Safety
L-arabinose has a reassuring profile. It's a naturally occurring plant sugar consumed in ordinary food, it's poorly absorbed, and no serious adverse effects appeared in the trials here.
The predictable issue is gastrointestinal. Undigested sucrose passing into the large intestine is fermented by gut bacteria, which means gas, bloating and loose stools — the same mechanism behind the well-known effects of sugar alcohols. This scales with dose and with how much sugar you eat, so the very scenario where L-arabinose does most is also the one most likely to be uncomfortable.
If you take glucose-lowering medication, anything that changes carbohydrate absorption can change your response to that medication — talk to your prescriber first. More on that here. This page is general information, not medical advice.
What I'd actually conclude
L-arabinose is more honest than most of what's in this category. The mechanism is specific, it has been tested properly, and it produced real numbers in the right conditions — a 30% reduction in insulin peak in prediabetic adults is a genuine result.
But the evidence defines a narrow window, and the marketing tends to present the ceiling as the floor. Three trials agree that the effect belongs to sugary liquids, not to meals. The mechanism is powerless against starch. And the doses that worked are measured in grams, which no multi-ingredient capsule can deliver.
So: if you drink sweet drinks and want to blunt the curve, several grams of L-arabinose stirred into the drink is a defensible, evidence-based thing to do — and you can buy bulk L-arabinose for that. If you're eating ordinary meals and hoping a capsule containing an undisclosed fraction of 525 mg will flatten them, the evidence doesn't support that expectation, and it's the dose and the timing that break it rather than the ingredient itself.
And as always, the boring free thing beats it: eating your vegetables and protein before your starch works on every meal, costs nothing, and doesn't depend on food matrix.
References
- In vitro inhibition of intestinal sucrase and maltase by L-arabinose is summarised in the background of Halschou-Jensen et al. (2015), reference 4 below.
- Pol K, Mars M. L-arabinose and D-xylose: sweet pentoses that may reduce postprandial glucose and insulin responses. Food Nutr Res. 2021;65. PMID 34393698
- Pretorius L, Pol K, Perenboom C, Appleton KM, James J, Mars M. Effects of L-Arabinose on Glycemic Responses After the Consumption of Sucrose-Rich Foods in Individuals with Impaired Fasting Glucose: A Randomized Controlled Cross-Over Trial. J Nutr. 2025;155(9):3030-9. PMID 40615089
- Halschou-Jensen K, Bach Knudsen KE, Nielsen S, Bukhave K, Andersen JR. A mixed diet supplemented with L-arabinose does not alter glycaemic or insulinaemic responses in healthy human subjects. Br J Nutr. 2015;113(1):82-8. PMID 25400106
Medical disclaimer. General information written by a layperson, not medical advice. L-arabinose is a dietary supplement ingredient; nothing here diagnoses, treats, cures or prevents any disease, including diabetes. Talk to a qualified healthcare professional before starting any supplement, particularly if you take medication.